BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 560 filers reported holding BIO-TECHNE CORP in Q2 2024. The put-call ratio across all filers is 0.33 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $610,873 | +51.0% | 8,525,772 | +48.4% | 0.07% | +46.0% |
Q1 2024 | $404,470 | +75.3% | 5,746,119 | +92.1% | 0.05% | +61.3% |
Q4 2023 | $230,791 | -12.1% | 2,991,054 | -22.5% | 0.03% | -18.4% |
Q3 2023 | $262,593 | -20.9% | 3,857,666 | -5.2% | 0.04% | -17.4% |
Q2 2023 | $332,025 | +781.5% | 4,067,429 | +701.2% | 0.05% | +666.7% |
Q1 2023 | $37,664 | -57.5% | 507,648 | -52.5% | 0.01% | -57.1% |
Q4 2022 | $88,624 | -99.9% | 1,069,311 | +268.6% | 0.01% | +7.7% |
Q3 2022 | $82,379,000 | -5.5% | 290,065 | +15.3% | 0.01% | +18.2% |
Q2 2022 | $87,181,000 | -22.3% | 251,502 | -3.0% | 0.01% | 0.0% |
Q1 2022 | $112,264,000 | -19.6% | 259,246 | -3.9% | 0.01% | -15.4% |
Q4 2021 | $139,595,000 | +20.8% | 269,832 | +13.2% | 0.01% | +18.2% |
Q3 2021 | $115,554,000 | +63.1% | 238,468 | +51.6% | 0.01% | +57.1% |
Q2 2021 | $70,831,000 | +9.0% | 157,312 | -7.6% | 0.01% | 0.0% |
Q1 2021 | $65,007,000 | +14.5% | 170,207 | -4.8% | 0.01% | +16.7% |
Q4 2020 | $56,771,000 | +30.1% | 178,777 | +1.5% | 0.01% | +20.0% |
Q3 2020 | $43,639,000 | +29.6% | 176,156 | +38.1% | 0.01% | +25.0% |
Q2 2020 | $33,674,000 | +795.6% | 127,519 | +543.1% | 0.00% | +300.0% |
Q1 2020 | $3,760,000 | -17.1% | 19,830 | -4.0% | 0.00% | 0.0% |
Q4 2019 | $4,535,000 | +13.4% | 20,661 | +1.1% | 0.00% | 0.0% |
Q3 2019 | $3,998,000 | -4.9% | 20,434 | +1.4% | 0.00% | 0.0% |
Q2 2019 | $4,203,000 | +8.1% | 20,161 | +3.0% | 0.00% | 0.0% |
Q1 2019 | $3,888,000 | +46.1% | 19,582 | +6.5% | 0.00% | – |
Q4 2018 | $2,661,000 | -9.7% | 18,390 | +27.4% | 0.00% | – |
Q3 2018 | $2,946,000 | +38.1% | 14,431 | +0.0% | 0.00% | – |
Q2 2018 | $2,134,000 | -1.8% | 14,424 | +0.2% | 0.00% | – |
Q1 2018 | $2,174,000 | +17.1% | 14,395 | +0.5% | 0.00% | – |
Q4 2017 | $1,856,000 | -6.6% | 14,330 | -12.9% | 0.00% | – |
Q3 2017 | $1,988,000 | +3.0% | 16,446 | +0.1% | 0.00% | – |
Q2 2017 | $1,930,000 | +24.4% | 16,426 | +7.6% | 0.00% | – |
Q1 2017 | $1,551,000 | +8.5% | 15,262 | +9.7% | 0.00% | – |
Q4 2016 | $1,430,000 | -6.1% | 13,909 | +0.0% | 0.00% | – |
Q3 2016 | $1,523,000 | -21.5% | 13,907 | -19.2% | 0.00% | – |
Q2 2016 | $1,940,000 | +12.9% | 17,207 | -5.4% | 0.00% | – |
Q1 2016 | $1,718,000 | +23.2% | 18,181 | +17.4% | 0.00% | – |
Q4 2015 | $1,394,000 | -35.1% | 15,491 | -33.3% | 0.00% | – |
Q3 2015 | $2,147,000 | -6.0% | 23,223 | +0.1% | 0.00% | – |
Q2 2015 | $2,284,000 | +19.1% | 23,193 | +21.3% | 0.00% | – |
Q1 2015 | $1,918,000 | +14.6% | 19,123 | +5.6% | 0.00% | – |
Q4 2014 | $1,674,000 | – | 18,113 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |